(SEATTLE), May 20, 2020 -- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio. The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine.
(SEATTLE), May 14, 2020 -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event. BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine.
AGC Biologics will manufacture novel precision cancer immunotherapy treatment Clevegen
(SEATTLE), May 5, 2020 -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has been selected to commercially manufacture the treatment Clevegen for partner Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company. Clevegen is a humanized anti-Clever-1 antibody which targets CLEVER-1 positive tumour associated macrophages (TAMs) and converts these highly immunosuppressive M2 macrophages to immune stimulating M1 macrophages. This unique macrophage-directed immuno-oncology switch may be used alone or in combination with other cancer treatments.
The drug, Leronlimab, owned by CytoDyn, containing a special molecule manufactured by AGC Biologics, is showing favorable results in the treatment of severely affected COVID-19 patients. AGC Biologics stands ready to ramp up manufacturing to meet demand once this drug is FDA approved.
(SEATTLE), April 23, 2020 -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it is partnering with AdaptVac to develop and produce a COVID-19 vaccine. AdaptVac, together with its EU Horizon 2020 sponsored PREVENT-nCoV consortium partners, are developing a SARS-CoV-2 vaccine. The COVID-19 pandemic is still evolving, and AdaptVac’s Virus-Like Particle (VLP) technology could provide a solution to protect against new SARS-CoV-2 infections.
AGC Biologics Sponsors 14th Annual BIO-Europe Spring Conference
For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners via BIO one-on-one partnering, education resources to help drive your business, and the insights you need to continue critical research and development.
We may not be able to gather in person, but nothing stops innovation.
Engage with AGC Biologics at Europe's largest fall biotech partnering event. Email us at email@example.com to set up a meeting or contact us via our website https: www.agcbio.com/contact_us/.
We're looking forward to attending MIXiii BIOMED in Tel Aviv, Israel. Will you be joining us there? If you would like to set up a meeting, please email us at firstname.lastname@example.org or contact us via our website http://agcbio.com/contactus
This year's event in Tel Aviv will expand the scope and range of topics to explore trends and innovations which are shaping the future of the healthcare system to its full extent. It will discuss prevention, diagnosis, monitoring and treatment domains, emphasizing quality of life extension. In all topics they will feature Medical Device, Biopharma, Digital Health and Diagnosis where appropriate.
This year's event in Munich will bring together the "who's who" from the biotech, pharma and finance segments to allow delegates to meet more key decision makers in three days of partnering meetings than they could in a whole year. Learn More